IgA-FcRn Engagement based IgA Half-Life Extension Services
Background Service Highlights Workflow Contact
Redefining IgA Pharmacokinetics through Rational FcRn-Targeted Design
Immunoglobulin A (IgA) is the predominant antibody at mucosal surfaces and plays a critical role in frontline immune defense. Despite its therapeutic promise, especially in respiratory, gastrointestinal, and mucosal infections, one of the major hurdles for systemic application of IgA-based therapeutics is its short half-life in serum. In contrast to IgG, which engages the neonatal Fc receptor (FcRn) for pH-dependent recycling and extended circulation, native IgA lacks efficient FcRn binding, leading to rapid clearance from the bloodstream.
At Creative Biolabs, we provide specialized IgA-FcRn Engagement-Based Half-Life Extension Services aimed at overcoming this pharmacokinetic limitation. Through advanced antibody engineering, molecular fusion, and structural optimization strategies, we help researchers and drug developers design IgA variants that can actively engage FcRn and benefit from prolonged in vivo stability.
What We Offer
Our FcRn engagement platform is built on structural biology, immunoglobulin domain engineering, and recombinant expression expertise. We provide two complementary and customizable strategies:
IgA-Albumin Binding Domain (Abd) Fusion Protein Production Service
Human serum albumin (HSA) is a long-circulating plasma protein that naturally engages FcRn. By fusing IgA with albumin-binding domains (Abd), we can indirectly leverage this pathway to extend the half-life of IgA therapeutics.
Service Highlights:
- Design & Optimization: Engineering of IgA-Abd fusion constructs with flexible linkers to preserve antigen specificity and effector function.
- Expression & Purification: Recombinant production in mammalian systems (CHO/HEK293) with optional co-expression of J-chain or pIgR for dimeric formats.
- FcRn-Dependent Binding: Assay development to confirm FcRn engagement via albumin mediation at acidic and neutral pH.
- Pharmacokinetic Profiling: In vitro FcRn recycling assays and optional in vivo PK studies in FcRn-transgenic models.
Click the key words to learn more!
IgA-FcRn Binding Motif Engineering Service
A more direct approach involves rational design of IgA variants containing engineered FcRn-binding motifs. While IgA1 and IgA2 Fc regions natively lack such motifs, site-specific amino acid substitutions at the CH2-CH3 interface or IgG-inspired motif grafting can be used to introduce FcRn engagement.
Service Highlights:
- Structure-Guided Mutagenesis: Computational modeling to identify candidate residues for mutation without disrupting IgA structure or FcαRI binding.
- Motif Grafting: Introduction of known IgG FcRn binding motifs (e.g., M252Y/S254T/T256E) into IgA Fc domain scaffolds.
- Variant Screening: High-throughput screening for FcRn affinity (SPR or ELISA-based), thermal stability, and expression efficiency.
- Function Preservation: Evaluation of antigen binding, dimerization (for IgA polymers), and Fc receptor engagement.
Click the key words to learn more!
Why This Matters
The ability to extend IgA's serum persistence unlocks its use in systemic immunotherapy, chronic disease treatment, and long-acting prophylaxis. Furthermore, engineered IgA can retain its mucosal trafficking properties while functioning efficiently in peripheral circulation—something previously unattainable with native IgA formats.
- Systemic treatment of mucosal pathogens (e.g., Streptococcus pneumoniae, Neisseria gonorrhoeae)
- IgA checkpoint blockade antibodies for cancer immunotherapy
- IgA-biologics for chronic autoimmune inflammation
- Long-acting delivery platforms for mucosal vaccine adjuvants
Service Workflow
Our FcRn engagement services follow a streamlined, modular process:
Each project is tailored to your IgA subclass (IgA1 or IgA2), antigen specificity, and intended application.
Partner with Creative Biolabs
Creative Biolabs brings unmatched experience in antibody engineering and Fc biology, supported by a strong track record in delivering advanced FcRn-related solutions. Whether you are developing a novel IgA-based therapeutic or optimizing an existing lead for better pharmacokinetics, our IgA-FcRn Engagement platform offers the depth, precision, and flexibility you need to succeed.
Contact us today to discuss how we can extend the therapeutic reach of your IgA molecule through next-generation FcRn engagement strategies.
For research use only. Not intended for any clinical use.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
